Winnipeg – May 1, 2026 – TheNewswire — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO; FSE: 70G) announces that, as disclosed in the Company’s management’s discussion and analysis for the year ended December 31, 2025 filed on April 30, 2026, Mr. Will Ollerhead has resigned as a director of the Company effective April 29, 2026, to focus on other endeavors. The Company thanks him for his service and contributions during his tenure as a director and wishes him continued success in the future.
About Cytophage
Cytophage (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.
For more information on Cytophage, please visit www.cytophage.com.
For further information please contact:
Cytophage Technologies Ltd.
Steven Theriault, Chief Executive Officer: steven@cytophagetech.com
Investor Relations: info@cytophage.com
Cytophage Investor Alerts: https://cytophage.com/subscribe/
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
